Skip to main content
Real-world evidence for COSELA
Navbar Image
Real-world evidence for COSELA
This site is intended only for US healthcare professionals.

Real-world evidence for COSELA

Lower incidence of neutropenia-related consequences with COSELA in a real-world study1,a

RATES OF NEUTROPENIA AND G-CSF ADMINISTRATIONb

  • Fewer white blood cell-related events from chemotherapy in patients receiving COSELA in a real-world study, including1:
    • Severe neutropenia after cycle 1 (primary endpoint)
    • Severe neutropenia throughout the treatment period (primary endpoint)
    • Grade 3 neutropenia (secondary endpoint)
    • Febrile neutropenia (secondary endpoint)
    • G-CSF administration (secondary endpoint)
  • Although adverse events were not specifically mentioned in the publication, reported fatal adverse events in the clinical trials for COSELA included pneumonia, respiratory failure, acute respiratory failure, hemoptysis, and cerebrovascular accident
See the Study Design
G-CSF=granulocyte colony-stimulating factor.
a
Additional neutropenia-related consequences were not studied.
b
Of the 62 patients identified who received etoposide/carboplatin/atezolizumab + COSELA, 34 met the inclusion criteria for review. Inconsistent COSELA utilization from cycle 2 and onward was the most common reason for exclusion (n=11). Likewise, 44 patients in the non-COSELA cohort were included for review from an initial list of 65 patients. Lost to follow-up (n=7) and carboplatin area under the curve <3.5 with cycle 1 (n=6) were the most common reasons for exclusion.1
c
Indicates statistical significance.
Real-world evidence is observational and may be subject to limitations, including lack of randomization.